Currently set to Index
Currently set to Follow
National Coalition for Cancer Survivorship - State of Survivorship Survey
National Coalition for Cancer Survivorship - State of Survivorship Survey

The State of Cancer Survivorship

The National Coalition for Cancer Survivorship (NCCS) conducts an annual State of Survivorship Survey, in partnership with Edge Research, to delve into the cancer patient and survivor journey. New this year, we’ve added a companion survey for caregivers. This study captures a range of perspectives to better understand how NCCS can support its mission to advocate for quality cancer care for all.

Take the 2023 Survivorship Survey!

Do you have a history of cancer or have you cared for someone diagnosed with cancer? If so, you may be eligible to take the 2023 State of Cancer Survivorship Survey.

The responses will help us understand how we can better address the survivorship needs of patients and survivors. This survey is for research purposes only and your opinions will help inform NCCS’s future work.

  • The survey is available in English and Spanish.
  • The survey will take approximately 15 minutes to complete.
  • Responses will remain strictly confidential. The information you provide will only be viewed together with the responses of others. Your information will never be sold to a third party.

Survey Reports


The 2022 Survey found significant disparities in cancer care that impact people of color, young adults, women, and those with metastatic cancer, at higher rates.


2021 Survivorship Survey report thumbnail
The 2021 Survey demonstrated that when patients receive quality care, have excellent support, and have financial resources, they are more likely to have positive outcomes.


2020 Survivorship Survey Report cover
In the 2020 Survey, survivors reported that their care team is not helpful at addressing some common side effects of their cancer such as fatigue, anxiety, and depression.

Program Supporters

Survivorship Survey Sponsors 2023 - Grail, Pfizer, Bristol Myers Squibb, Exelixis